Results 81 to 90 of about 7,204,824 (312)

DRLS, drug establishment registration and drug listing instruction booklet.

open access: yes, 1991
Shipping list no.: 91-422-P.At head of title: DRLS, Drug Registration and Listing System.Mode of access ...
Center for Drug Evaluation and Research (U.S.). Drug Listing Branch.
core  

External review of the IDRC Evaluation Unit [PDF]

open access: yes, 2010
French version available in IDRC Digital Library: Constatations en bref de l'examen externe de la Section de l'évaluation du CRDIThis brief is based on the "Report on the 2010 External Review of the IDRC Evaluation Unit" by Ailish Byrne, Ian C.
IDRC. Evaluation Unit
core   +1 more source

Preclinical pharmacokinetic evaluation of novel antimalarial and antituberculosis drug leads [PDF]

open access: yes, 2019
Preclinical pharmacokinetics relies on efficient and accurate screening to select clinical candidates from early leads. Poor pharmacokinetic interpretation can disadvantage drug discovery by promoting inadequate compounds and expelling potential drug ...
Strydom, Natasha
core   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

open access: yesMolecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla   +4 more
wiley   +1 more source

Supplementary Figure from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors

open access: yes, 2022
Supplementary Figure from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing ...
Jeff Hooley (15084369)   +30 more
core   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

open access: yesMolecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho   +2 more
wiley   +1 more source

Human Cardiac Organoids: Advances and Prospects from Construction to Preclinical Drug Evaluation

open access: yesCells
Drug-induced cardiotoxicity (DICT) severely hampers drug development and threatens patient safety. Together with the growing global burden of cardiovascular disease, there is an urgent need to establish more predictive preclinical models. Recently, human
Meng Chen   +9 more
doaj   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

open access: yesMolecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee   +3 more
wiley   +1 more source

New South Wales drug court evaluation: Cost-effectiveness, CHERE Project Report 17a [PDF]

open access: yes
In this report we examine an issue central to the creation of the NSW Drug Court: namely its cost-effectiveness, compared with conventional sanctions, in reducing drug-related crime.
Marion Haas   +5 more
core  

Supplementary Data from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors

open access: yes, 2022
Supplementary Data from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing ...
Jeff Hooley (15084369)   +30 more
core   +1 more source

Home - About - Disclaimer - Privacy